Erlotinib Hydrochloride

"Erlotinib Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

Descriptor ID	D000069347
MeSH Number(s)	D03.633.100.786.375
Concept/Terms	Erlotinib Hydrochloride Erlotinib Hydrochloride Hydrochloride, Erlotinib Erlotinib HCl HCl, Erlotinib OSI-774 OSI-774 OSI 774 OSI774 CP 358774 CP 358774 358774, CP CP 358,774 358,774, CP CP-358,774 CP358,774 CP-358774 CP358774 11C-erlotinib 11C-erlotinib 11C erlotinib Erlotinib Erlotinib N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Tarceva Tarceva

Below are MeSH descriptors whose meaning is more general than "Erlotinib Hydrochloride".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Quinazolines [D03.633.100.786]
Erlotinib Hydrochloride [D03.633.100.786.375]

Below are MeSH descriptors whose meaning is related to "Erlotinib Hydrochloride".

Below are MeSH descriptors whose meaning is more specific than "Erlotinib Hydrochloride".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Erlotinib Hydrochloride" by people in this website by year, and whether "Erlotinib Hydrochloride" was a major or minor topic of these publications.

Bar chart showing 17 publications over 11 distinct years, with a maximum of 3 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2007	0	2	2
2008	0	2	2
2011	0	1	1
2012	0	2	2
2014	0	1	1
2015	3	0	3
2016	0	2	2
2018	1	0	1
2022	0	1	1
2023	0	1	1
2024	0	1	1

Below are the most recent publications written about "Erlotinib Hydrochloride" by people in Profiles.

Leylek O, Honeywell ME, Lee MJ, Hemann MT, Ozcan G. Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy. Gastric Cancer. 2024 Nov; 27(6):1201-1219.

View in: PubMed
Dookwah M, Wagner SK, Ishihara M, Yu SH, Ulrichs H, Kulik MJ, Zeltner N, Dalton S, Strauss KA, Aoki K, Steet R, Tiemeyer M. Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants. Hum Mol Genet. 2023 12 01; 32(24):3323-3341.

View in: PubMed
Campos S, Matulonis U, Berlin S, Horowitz N, Liu J, Krasner C, Hang L, Zarwan C, Barry W, Colella T, Whalen C, Shoni M, Lundquist C, Birrer MJ, Penson R. A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. Int J Clin Oncol. 2022 Dec; 27(12):1881-1890.

View in: PubMed
Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung Cancer. 2018 03; 117:44-49.

View in: PubMed
Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN, Gandara DR, Perez-Soler R. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):60-67.

View in: PubMed
Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016 05 09; 29(5):639-652.

View in: PubMed
Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar; 11(3):420-5.

View in: PubMed
Ji Y, Schwartz J, Hartford A, Ramsey J, Phillips J, Verschraegen C. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy. JAMA Oncol. 2015 Sep; 1(6):838-40.

View in: PubMed
Boucher J, Lucca J, Hooper C, Pedulla L, Berry DL. A Structured Nursing Intervention to Address Oral Chemotherapy Adherence in Patients With Non-Small Cell Lung Cancer. Oncol Nurs Forum. 2015 Jul; 42(4):383-9.

View in: PubMed
Morton SW, Lee MJ, Deng ZJ, Dreaden EC, Siouve E, Shopsowitz KE, Shah NJ, Yaffe MB, Hammond PT. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal. 2014 May 13; 7(325):ra44.

View in: PubMed

People

Explore

Similar Concepts

Top Journals